Renal Cell Carcinoma (Post nr. 6888)

MARC-detaljer
000 -LEADER
fixed length control field	03936nam a22004575i 4500
001 - CONTROL NUMBER
control field	60555
005 - DATE AND TIME OF LATEST TRANSACTION
control field	20200226102543.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field	cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field	170215s2017 ja \| s \|\|\|\| 0\|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number	9784431555315
--	978-4-431-55531-5
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code	10.1007/978-4-431-55531-5
Source of number or code	doi
035 ## - SYSTEM CONTROL NUMBER
System control number	(DE-He213)978-4-431-55531-5
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number	RC254-282
072 #7 - SUBJECT CATEGORY CODE
Subject category code	MJCL
Source	bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code	MED062000
Source	bisacsh
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number	616.994
Edition number	23
245 10 - TITLE STATEMENT
Title	Renal Cell Carcinoma
Medium	[electronic resource] :
Remainder of title	Molecular Features and Treatment Updates /
Statement of responsibility, etc.	edited by Mototsugu Oya.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture	Tokyo :
Name of producer, publisher, distributor, manufacturer	Springer Japan :
--	Imprint: Springer,
Date of production, publication, distribution, manufacture, or copyright notice	2017.
300 ## - PHYSICAL DESCRIPTION
Extent	X, 381 p. 78 illus., 54 illus. in color.
Other physical details	online resource.
336 ## - CONTENT TYPE
Content type term	text
Content type code	txt
Source	rdacontent
337 ## - MEDIA TYPE
Media type term	computer
Media type code	c
Source	rdamedia
338 ## - CARRIER TYPE
Carrier type term	online resource
Carrier type code	cr
Source	rdacarrier
347 ## - DIGITAL FILE CHARACTERISTICS
File type	text file
Encoding format	PDF
Source	rda
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note	Chapter 1 Epidemiology of Renal Cell Carcinoma -- Chapter 2 Hereditary Renal Cell Carcinoma -- Chapter 3 Molecular Genetics of Renal Cell Carcinoma -- Chapter 4 Pathology of Renal Cell Carcinoma -- Chapter 5 Imaging Features of Renal Cell Carcinoma: Differential Diagnosis, Staging and Post-Treatment Evaluation -- Chapter 6 Treatment Overview -- Chapter 7 Natural History and Active Surveillance -- Chapter 8 Surgical Treatment for Renal Cell Carcinoma -- Chapter 9 Predictive and Prognostic Markers in Metastatic Renal Cell Carcinoma -- Chapter 10 Tyrosine-Kinase Inhibitors: Sorafenib, Sunitinib, Axitinib, Pazopanib -- Chapter 11 Mammalian Targets of Rapamycin Inhibitors: Temsirolimus, Everolimus -- Chapter 12 Immunotherapy for Renal Cell Carcinoma (RCC): Including Immune Checkpoint Blockade Therapy -- Chapter 13 Treatment for Non-Clear Cell Renal Cell Carcinoma -- Chapter 14 Forthcoming Drugs for Metastatic Renal Cell Carcinoma Therapy -- Chapter 15 Refractory Mechanisms -- Chapter 16 Optimization of Therapy by Pharmacokinetic: Pharmacodynamic Analyses.
520 ## - SUMMARY, ETC.
Summary, etc.	This book provides a comprehensive review of diagnosis and treatments of renal cell carcinoma (RCC) for practitioners and researchers with an interest in this disease. A major aim of the book is to present the most important and most recent advances in molecular bases and targeted therapy for this neoplasm. The remarkable resistance to chemotherapy and radiotherapy and the minimum contribution of cancer genes that commonly mutate in other adult epithelial cancers have made RCC highly distinct from other types of solid neoplasms. In the past decade, however, treatment options for RCC have been expanding and moving quickly toward laboratory-based and molecular-targeted therapies. Advances in RCC therapy also have brought novel treatment options to other types of cancer, such as a TKI for hepatocellular carcinoma and gastrointestinal tumors, as well as mTOR inhibitors to progressive neuroendocrine tumors of pancreatic origin and to breast cancer, suggesting that RCC is no longer an "orphan disease" in the field of molecular oncology. Additional topics covered in the book include pharmacokinetics and pharmacodynamics in molecular-targeted agents and the putative mechanism of resistance to anti-angiogenic agents, such as intratumoral heterogeneity or cancer stem cell population. This volume provides the latest and most useful information for all readers who are eagerly devoted to curing renal cell carcinoma.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element	Medicine.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element	Molecular biology.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element	Oncology.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element	Urology.
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element	Medicine & Public Health.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element	Oncology.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element	Urology.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element	Molecular Medicine.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name	Oya, Mototsugu.
Relator term	editor.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element	SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title	Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Relationship information	Printed edition:
International Standard Book Number	9784431555308
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier	<a href="http://dx.doi.org/10.1007/978-4-431-55531-5">http://dx.doi.org/10.1007/978-4-431-55531-5</a>
912 ## -
--	ZDB-2-SME

Inga exemplar finns tillgängliga.